Peak Bio, Inc.
PKBODelisted Mar 3, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001834645
Peak Bio, Inc. was delisted on Mar 3, 2023; its insiders filed their last Form 4 on Dec 4, 2024; 9 institutions reported holding it in 13F filings for Q4 2022, worth $2.53M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 9
- Q4 2022, +8 vs. previous quarter
- 13F value
- $2.53M
- Reported value at the end of Q4 2022
- Superinvestors holding
- 0
- At the end of Q4 2022
Superinvestors holding PKBO, Q4 2022
No superinvestor reported holding PKBO at the end of Q4 2022.
Latest insider trades
Open-market purchases and sales by Peak Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 28, 2023 (view filing) | Sep 26-27 | 2 days | LaMond Stephen JSee Remarks | PPurchase | +5.60K | – | – | +39.3%19.9K after | 2 lots |
| Sep 28, 2023 (view filing) | Sep 15-18 | 13 days | LaMond Stephen JSee Remarks | PPurchase | +14.3K | – | – | New position14.3K after | Amended2 lots |
| Sep 25, 2023 (view filing) | Sep 21 | 4 days | Huh HoyoungDirector, 10% Owner | PPurchase | +45.0K | – | – | +0.5%8.38M after | |
| Sep 21, 2023 (view filing) | Sep 19-20 | 2 days | Huh HoyoungDirector, 10% Owner | PPurchase | +80.0K | – | – | +1.0%8.34M after | 2 lots |
| Sep 19, 2023 (view filing) | Sep 15 | 4 days | Huh HoyoungDirector, 10% Owner | PPurchase | +25.0K | – | – | +0.3%8.26M after | |
| Sep 15, 2023 (view filing) | Sep 13-14 | 2 days | Huh HoyoungDirector, 10% Owner | PPurchase | +50.0K | – | – | +0.6%8.23M after | 2 lots |
| Sep 13, 2023 (view filing) | Sep 11-12 | 2 days | Huh HoyoungDirector, 10% Owner | PPurchase | +47.0K | – | – | +0.6%8.18M after | 2 lots |
| Sep 12, 2023 (view filing) | Aug 29-31 | 14 days | Huh HoyoungDirector, 10% Owner | PPurchase | 0 | – | $0 | 0.0%8.14M after | Amended7 lots |
Top 10 13F holders, Q4 2022
The largest institutional positions in Peak Bio, Inc. at the end of Q4 2022; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Palo Alto Investors LP | 497,528 | $2.02M | 0.17% | +497,528 | New |
| Geode Capital Management, LLC | 51,092 | $214.0K | 0.00% | +51,092 | New |
| Charles Schwab Investment Management Inc | 38,631 | $161.9K | 0.00% | +38,631 | New |
| Northern Trust Corp | 14,382 | $60.3K | 0.00% | +14,382 | New |
| Goldman Sachs Group Inc | 13,716 | $57.5K | 0.00% | +13,716 | New |
| Tower Research Capital LLC (TRC) | 3,161 | $14.0K | 0.00% | +3,161 | New |
| UBS Group AG | 719 | $3.01K | 0.00% | +719 | New |
| Morgan Stanley | 278 | $1.17K | 0.00% | +278 | New |
| Wells Fargo & Company | 49 | $205 | 0.00% | +49 | New |